- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02021409
Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934 (DIALOGUE 2)
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Darbepoetin Alfa) in the Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment in Europe and Asia Pacific
Anaemia is a condition in which blood has a lower than normal number of red blood cells. It can also occur if red blood cells do not contain enough haemoglobin, an oxygen carrying part of blood. Anaemia is common in patients with chronic kidney disease. Healthy kidneys produce a hormone called erythropoietin, which stimulates the bone marrow to produce the proper number of red blood cells needed to carry oxygen to vital organs. Chronic kidney disease is a general term that means that the kidneys are not functioning to their full potential. The study drug, BAY85-3934, is being evaluated as a drug to increase the body's ability to produce erythropoietin.
The purpose of this study is to find out if the study drug, a tablet taken orally, is safe and effective for the treatment of anaemia associated with chronic kidney disease.
The study will enroll 120 patients at multiple locations in Europe, Asia and Australia. Participation will involve a screening visit and between 12 and 15 study visits scheduled over a period of approximately 5 to 7 months. The estimated total duration of study treatment will be 16 weeks. During these scheduled visits patients will undergo a number of procedures to confirm efficacy and safety of the study drug, including measurement of heart rate and blood pressure, physical examination, Electrocardiogram and blood/urine sample collection for laboratory tests.
The study will be conducted at 3 hospitals in the UK. Bayer HealthCare AG is funding this research.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Nordrhein-Westfalen
-
Bonn, Nordrhein-Westfalen, Alemania, 53127
-
-
-
-
New South Wales
-
Gosford, New South Wales, Australia, 2250
-
-
Victoria
-
Reservoir, Victoria, Australia, 3073
-
-
-
-
-
Dobrich, Bulgaria, 9300
-
Lovech, Bulgaria, 5500
-
Montana, Bulgaria, 3400
-
Pazardjik, Bulgaria, 4400
-
Sofia, Bulgaria, 1872
-
Stara Zagora, Bulgaria, 6000
-
-
-
-
Gyeonggido
-
Bucheon-si, Gyeonggido, Corea, república de, 420-767
-
-
-
-
-
Madrid, España, 28007
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, España, 08907
-
-
Madrid
-
San Sebastián de los Reyes, Madrid, España, 28702
-
-
-
-
-
Grenoble Cedex 9, Francia, 38043
-
Pierre Benite Cedex, Francia, 69495
-
-
-
-
-
Baja, Hungría, 6500
-
Budapest, Hungría, 1036
-
Esztergom, Hungría, 2500
-
Kaposvar, Hungría, 7400
-
Pecs, Hungría, 7624
-
Szigetvar, Hungría, 7900
-
-
-
-
-
Ashkelon, Israel, 7827804
-
Hadera, Israel, 3810101
-
Kfar Saba, Israel, 4428164
-
Nahariya, Israel, 2210001
-
-
-
-
Campania
-
Napoli, Campania, Italia, 80138
-
-
Lombardia
-
Brescia, Lombardia, Italia, 25123
-
Cremona, Lombardia, Italia, 26100
-
Lecco, Lombardia, Italia, 23900
-
Pavia, Lombardia, Italia, 27100
-
-
Toscana
-
Livorno, Toscana, Italia, 57023
-
-
-
-
-
Chiba, Japón, 260-8712
-
Fukuoka, Japón, 810-8563
-
Nagano, Japón, 388-8004
-
-
Fukuoka
-
Kitakyushu, Fukuoka, Japón, 802-8555
-
Okawa, Fukuoka, Japón, 831-0016
-
-
Hokkaido
-
Muroran, Hokkaido, Japón, 050-0083
-
-
Iwate
-
Morioka, Iwate, Japón, 020-0066
-
-
Kanagawa
-
Fujisawa, Kanagawa, Japón, 251-8550
-
-
Mie
-
Kuwana, Mie, Japón, 511-0061
-
-
-
-
-
Ankara, Pavo, 06100
- Ankara Univ. Medical Faculty
-
Ankara, Pavo, 06490
- Baskent University Medical Faculty
-
Izmir, Pavo, 03540
- Sifa University Medical Faculty
-
-
-
-
-
Bialystok, Polonia, 15-540
-
Radom, Polonia, 26-610
-
-
-
-
-
Liverpool, Reino Unido, L7 8XP
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Reino Unido, CB2 0QQ
-
-
-
-
-
Bucharest, Rumania, 010731
-
Bucharest, Rumania, 020475
-
Oradea, Rumania, 410469
-
Targu-Mures, Rumania, 540103
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female subjects ≥ 18 years of age with anemia of chronic kidney disease (CKD) at screening
- Estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73 m2 (Modification of Diet in Renal Disease or the formula according to Matsuo, et al.)
- Not on dialysis and not expected to begin dialysis during the treatment period of the study (at least 16 weeks from randomization)
- Treated with darbepoetin via intravenous (IV) or subcutaneous (SC) route with a weekly, bi-weekly, or monthly dose, having had no more than one dose change within 8 weeks prior to randomization
- At least one kidney
- Mean screening hemoglobin (Hb) concentration of 10.0 to 12.0 g/dL
- Men who agree to use adequate contraception when sexually active or women without childbearing potential
Exclusion Criteria:
- Subjects with significant acute or chronic bleeding, such as overt gastrointestinal bleeding
- Active hemolysis or diagnosis of hemolytic syndrome
- History of myelodysplastic syndrome, multiple myeloma, marrow fibrosis, or pure red-cell aplasia (PRCA)
- History of hemosiderosis or hemochromatosis
- Hereditary hemoglobinopathies (such as sickle cell disease and thalassemia major)
- Aplastic anemia
- Chronic lymphoproliferative diseases
- Proliferative choroidal or retinal disease, such as neovascular age-related macular degeneration or proliferative diabetic retinopathy that is likely to require invasive treatment (intraocular injections or laser photocoagulation) during the study
- Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission
- Known hypersensitivity to the study drugs (active substances or excipients of the preparations)
- Uncontrolled and symptomatic hyperparathyroidism
- Uncontrolled active infection
- Previous or concurrent cancer except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively treated > 3 years prior to randomization
- Any allograft (including renal allograft) in place and on immunosuppressive therapy or a scheduled kidney transplant within the next 16 weeks (being on a waiting list does not exclude the subject)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: BAY85-3934 (25mg)
Fixed starting dose of 25 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits.
Titration occuring every 4-weeks will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose.
Total treatment time is 16 weeks.
Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
|
Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
|
Experimental: BAY85-3934 (50mg)
Fixed starting dose of 50 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits.
Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose.
Total treatment time is 16 weeks.
Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
|
Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
|
Experimental: BAY85-3934 (75mg)
Fixed starting doses of 75 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits.
Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose.
Total treatment time is 16 weeks.
Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
|
Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
|
Comparador activo: Darbepoetin alfa
Darbepoetin (intravenous or subcutaneous) will be administered according to the local label and titrated at the scheduled dose control visits.
Titration will be based on the subject's Hb response and tolerability of the prior dose.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Change in local laboratory hemoglobin level from baseline to the average during the last 4 weeks treatment period
Periodo de tiempo: Baseline and week 12 to 16
|
Baseline and week 12 to 16
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Maintenance in hemoglobin target range (10.0 to 12.0 g/dL)
Periodo de tiempo: Up to 16 weeks
|
Up to 16 weeks
|
Change in hemoglobin level
Periodo de tiempo: Baseline up to 16 weeks
|
Baseline up to 16 weeks
|
Number of patients with hemoglobin levels outside the target range
Periodo de tiempo: Week 12 to 16
|
Week 12 to 16
|
Dose level in the evaluation period
Periodo de tiempo: Week 12 to 16
|
Week 12 to 16
|
Duration of exposure on each dose level
Periodo de tiempo: Up to 16 weeks
|
Up to 16 weeks
|
Number of subjects requiring titration of dose
Periodo de tiempo: Up to 16 weeks
|
Up to 16 weeks
|
Number of participants with serious adverse events as a measure of safety and tolerability
Periodo de tiempo: Up to 16 weeks
|
Up to 16 weeks
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 15261
- 2013-001192-21 (Número EudraCT)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Insuficiencia Renal Crónica
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and Kidney... y otros colaboradoresReclutamientoEnfermedades Renales Crónicas | Fallo renal agudo | Lesión renal aguda | Insuficiencia Renal Aguda | Insuficiencia renal cronica | Insuficiencia Renal, Aguda | Insuficiencia Renal Aguda | Insuficiencia Renal Aguda | Insuficiencia Renal Aguda | Insuficiencia renal aguda | Insuficiencia Renal Crónica | Enfermedades... y otras condicionesEstados Unidos
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillTerminadoEnfermedades Renales Crónicas | Enfermedad Renal Crónica Etapa 5 | Enfermedad Renal Crónica etapa 4 | Enfermedad renal pediátrica | Enfermedad Renal Crónica etapa 3 | Enfermedad Renal Crónica Etapa V | Enfermedad renal crónica, estadio IV (grave) | Enfermedad Renal Crónica Etapa 2 | Enfermedad Renal...Estados Unidos
-
University Hospital, BordeauxMinistry of Health, FranceTerminadoTrasplante Renal | Enfermedad renal crónica en etapa terminal | Insuficiencia Renal Aguda SeveraFrancia
-
Wake Forest University Health SciencesStanford UniversityTerminadoTrasplante Renal | Rechazo Renal Agudo | Rechazo Renal Crónico | Rechazo de Trasplante Renal | Sistema Renina-AngiotensinaEstados Unidos
-
Faculdade de Ciências Médicas da Santa Casa de...TerminadoEnfermedad Renal Crónica | Diálisis renalBrasil
-
Outset MedicalTerminadoLesión renal aguda | Enfermedad renal en etapa terminal (ESRD) | Enfermedad renal en etapa terminal en diálisisEstados Unidos
-
Novartis PharmaceuticalsTerminadoHemodiálisis | Terapia de reemplazo renal | Enfermedad renal en etapa terminal (ESRD) | Trasplante Renal | Enfermedad renal crónica (ERC)Alemania, Estados Unidos, Bélgica, Italia, España, Croacia, Taiwán, Australia, Austria, Grecia, Corea, república de, Líbano, Chequia, Israel, Países Bajos, Eslovenia, Suiza, Tailandia, Noruega, Pavo, Suecia, Argentina, Brasil, Japón, Serbia, Federación Rusa y más
-
ArdelyxAstraZenecaTerminadoEnfermedad renal en etapa terminal | ESRD | Enfermedad Renal Crónica Etapa 5Estados Unidos
-
Vanessa Stadlbauer-Koellner, MDAustrian Science Fund (FWF)TerminadoFallo renal agudo | Insuficiencia renal cronicaAustria
-
Angiodynamics, Inc.TerminadoEnfermedad Renal Crónica | Lesión renal aguda | Fallo renal agudo | Insuficiencia renal crónica inducida por contrasteEstados Unidos
Ensayos clínicos sobre BAY85-3934
-
BayerTerminado
-
BayerTerminadoInsuficiencia Renal CrónicaAlemania
-
BayerTerminadoInsuficiencia Renal Crónica | AnemiaJapón
-
BayerTerminadoInsuficiencia Renal Crónica | AnemiaJapón
-
BayerTerminadoInsuficiencia Renal Crónica | AnemiaEstados Unidos, Japón
-
BayerTerminadoInsuficiencia Renal Crónica | AnemiaJapón
-
BayerTerminadoInsuficiencia Renal Crónica | AnemiaJapón
-
BayerTerminadoUn estudio de molidustat para la corrección de la anemia renal en sujetos sin diálisis (MIYABI ND-C)Insuficiencia Renal Crónica | AnemiaJapón